Genetic and environmental causes of hemorrhagic stroke
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
We will test whether specific genetic variants and environmental factors are linked to the risk of intracerebral hemorrhage in adults.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | State University of New York at Buffalo Academic / other |
| Locations | 7 sites (Chicago, Illinois and 6 other locations) |
| Trial ID | NCT00682695 on ClinicalTrials.gov |
What this trial studies
This observational study will perform deep DNA sequencing and gene expression analysis focused on the 1q22 genomic region to find genetic contributors to non-lobar intracerebral hemorrhage (ICH). The team will recruit about 500 non-lobar ICH cases (approximately 150 Black and 350 White) and 1,000 controls to correlate sequence variation with expression levels in the same samples. Findings will be replicated in larger datasets including thousands of additional ICH cases and CHARGE consortium participants with MRI white matter hyperintensity measurements. The work aims to link replicated GWAS signals to functional changes that may explain ICH risk and broader small vessel disease mechanisms.
Who should consider this trial
Good fit: Ideal candidates are adults (18+) who are residents at the recruitment center for at least six months and either have had a spontaneous non-traumatic intracerebral hemorrhage or are enrolled as control participants willing to provide blood and clinical information.
Not a fit: People with hemorrhages caused by trauma, brain tumor/metastases, or infection, those unable to consent, or people seeking direct therapeutic benefit are unlikely to benefit from this observational genetic study.
Why it matters
Potential benefit: If successful, the results could identify people at higher genetic risk for ICH and point to new targets for prevention or therapy.
How similar studies have performed: Previous GWAS work identified a replicated association at 1q22 that this study builds on, but deep sequencing and linked expression analyses at this locus remain less tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 or older * Resident (6 months or longer) within the recruitment center * Fulfillment of the criteria for spontaneous ICH * No evidence of trauma, brain tumor/metastases or infectious processes as a cause of the hemorrhage * Ability of the patient or legal representative to provide consent for an interview, blood pressure determinations and DNA sampling Exclusion Criteria: * N/A
Where this trial is running
Chicago, Illinois and 6 other locations
- University of Illinois Chicago — Chicago, Illinois, United States (Not_yet_recruiting)
- Baptist Health Louisville — Louisville, Kentucky, United States (Recruiting)
- University of Maryland — Baltimore, Maryland, United States (Recruiting)
- Massachusetts General Hospital — Boston, Massachusetts, United States (Recruiting)
- Columbia University — New York, New York, United States (Not_yet_recruiting)
- Duke University — Durham, North Carolina, United States (Recruiting)
- University of Cincinnati — Cincinnati, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Daniel Woo, MD — University of Cincinnati
- Study coordinator: Lee A Gilkerson, RN, BSN
- Email: Lee.gilkerson@uc.edu
- Phone: 513-558-6140
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.